Table 5: Association between VDR polymorphisms and the clinicopathological features in HCC subjects.

FokI C>TTumor sizeAdjusted OR95% CIAdjusted value

<30 mm%>30 mm%

CC5525.00%5726.39%1
CT10849.09%10950.46%1.0270.6511.620.543
TT5725.91%5023.15%1.1810.6952.0080.068

Cancer stage
III + IVI + II

CC4318.53%6429.91%1
CT10946.98%9946.26%1.6391.0212.6290.054
TT7034.48%5123.83%2.3351.3853.9360.001

Liver cirrhosis history
PresenceAbsence

CC4018.78%6730.04%1
CT9243.19%10647.53%1.454 0.899 2.352 0.127
TT8138.03%5022.42%2.714 1.602 4.596 <0.001

Lymph node metastasis
PresenceAbsence

CC4318.45%6429.77%1
CT9641.20%10247.44%1.4010.872.2560.038
TT7733.05%5425.12%2.1221.2623.570.004

Portal invasion
PresenceAbsence

CC5325.48%6227.19%1
CT11052.88%10244.74%1.260 0.843 1.991 0.326
TT4521.63%6428.07%0.820 0.482 1.411 0.470

Heavy alcohol intake, (%)
Yes No

CC4328.29%6727.02%1.000
CT7549.34%12650.81%0.927 0.575 1.496 0.757
TT3422.37%5522.18%0.963 0.543 1.710 0.898